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of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Objectives: The aim of this six-month open feasibility study was to evaluate skin blood
perfusion and clinical symptom changes during aminaphtone treatment in patients with
either primary or secondary Raynaud’s phenomenon to systemic sclerosis.
Methods: Ninety-two patients referring for Raynaud’s phenomenon have been enrolled
in November during routine clinical assessment, after informed consent. Aminaphtone
was administered 75 mg twice daily in addition to current treatments to forty-six patients.
Skin blood perfusion was measured by Laser Speckle Contrast Analysis (LASCA) at the
level of fingertips, periungual areas, dorsum and palm of hands, and face at baseline
(W0), after one (W1), four (W4), twelve (W12) and twenty-four (W24) weeks of treatment.
Raynaud’s condition score (RCS) and both frequency and duration of Raynaud’s attacks
were assessed at the same time.
Results: Compared with the control group, despite colder period of the year,
aminaphtone treated patients showed a progressive statistically significant increase of
blood perfusion, as well as a decrease of RCS, frequency of Raynaud’s attacks/day
and their duration, from W0 to W12 in all skin areas. From W12 to W24 no
further increase of blood perfusion was observed. The results were similar in both
primary and secondary Raynaud’s phenomenon patients. Five weeks after aminaphtone
discontinuation blood perfusion values were significantly higher than those at baseline
in the majority of skin areas.
Conclusion: This study demonstrates that aminaphtone treatment increases skin blood
perfusion and improves Raynaud’s phenomenon clinical symptoms, with sustained
efficacy up to 6 months, even in patients with systemic sclerosis. A randomized, blind,
controlled, clinical trial including a larger number of subjects is advisable to confirm
these early results.
Keywords: Raynaud phenomenon, aminaphtone, blood perfusion, systemic sclerosis, laser speckle contrast
analysis, microcirculation, clinical symptoms, Raynaud condition score
INTRODUCTION
Raynaud’s phenomenon (RP) is a vasospastic disorder causing discoloration of fingers, toes, and
occasionally other areas like nose and tongue, with classic triphasic expression: pallor (ischaemic
phase), followed by cyanosis (cyanotic phase) and lastly redness (reactive hyperemic phase)
(Herrick, 2012; Hughes and Herrick, 2016; Wigley and Flavahan, 2016). The pathogenesis of
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RP is still not entirely clear or understood, but recent insights
into the pathogenic mechanisms underlying RP include
vascular, neuronal and intravascular abnormalities which may
identify crucial key points and potential targets for therapeutic
intervention (Herrick, 2012; Hughes and Herrick, 2016;
Wigley and Flavahan, 2016).
Raynaud’s phenomenon is classified as primary (idiopathic,
not associated with any disease), or secondary to several clinical
conditions, such as connective tissue diseases, in particular
systemic sclerosis (SSc) (Bernero et al., 2013; Park et al., 2015).
Systemic sclerosis is characterized by a deregulation of
the vascular tone, in which RP is the most frequent clinical
manifestation, associated with structural damage and intimal
thickening of the vascular wall, which leads to reduced
blood flow and chronic tissue ischemia (Gabrielli et al.,
2009; Cutolo et al., 2010b; Kanno et al., 2017). In addition,
endothelial cell dysfunction, characterized by an imbalance
between vasoconstrictor and vasodilator mediators, is a
primary event in the pathogenesis of SSc, followed by fibrosis
(Gabrielli et al., 2009; Sulli et al., 2009; Corallo et al., 2016;
Hughes and Herrick, 2016).
In the last years, several clinical trials and observational studies
on RP have been published, reflecting the increased awareness
of the disease burden (Wigley et al., 1994, 1998; Fries et al.,
2005; Thompson and Pope, 2005; Gliddon et al., 2007; Cutolo
et al., 2014; Corallo et al., 2016). Pharmacological therapies
for treatment and prevention of RP include calcium channel
blockers, antiplatelet and anticoagulant drugs, endothelin
receptor antagonist, phosphodiesterase inhibitors, iloprost, and
statins (Wigley et al., 1994, 1998; Fries et al., 2005; Thompson
and Pope, 2005; Gliddon et al., 2007; Abou-Raya et al., 2008;
Herrick, 2013; Cutolo et al., 2014). However, current treatments
for RP have limited efficacy, which was mainly demonstrated by
physician/patient reported outcomes (PROs) (Wigley et al., 1994,
1998; Fries et al., 2005; Thompson and Pope, 2005; Gliddon et al.,
2007; Abou-Raya et al., 2008).
Aminaphtone is a synthetic derivative of 4-aminobenzoic
acid (2-hydroxy-3-methyl-1,4 apthohydroquinone-2-p-
aminobenzoatate), which has been used for more than
40 years in some European and South American countries
in the treatment of clinical consequences of microvascular
impairment (e.g., chronic venous insufficiency of the lower
limbs, ulcers of legs, and microangiopathy in diabetes) (De
Anna et al., 1989; Pereira de Godoy, 2010; Belczak et al., 2014;
Romano et al., 2014; Martinez-Zapata et al., 2016; Felice et al.,
2018). Recently, aminaphtone was reported to improve the
symptoms associated with RP, as well as to reduce endothelin-1
production on cultured human endothelial cells (Scorza et al.,
2008a; Parisi et al., 2015).
Laser speckle contrast analysis (LASCA) is a validated
technique that quantifies skin blood perfusion over an area
(Ruaro et al., 2014, 2016; Sulli et al., 2014; Lambrecht et al., 2016).
The aim of this longitudinal six-month open feasibility
study was to evaluate skin blood perfusion changes by
LASCA and RP-related clinical symptoms by PROs during
aminaphtone treatment, in patients with either primary RP or
secondary RP to SSc.
MATERIALS AND METHODS
Patients
Recruitment of all patients was performed in November 2016,
during routine clinical assessment, at the outpatient clinic of
the Division of Rheumatology of the University of Genova.
Patients were enrolled in November to carry out the study
during the six colder months of the year, in order to avoid that
seasonal variations of temperature could influence skin blood
perfusion assessment and study results. The study was conducted
in accordance with the principles of the Declaration of Helsinki
and Good Clinical Practice, and all patients provided written
informed consent.
Forty-six consecutive patients with active RP, asking for
treatment during standard clinical assessments, were recruited:
11 primary RP (mean age 49 ± 19 SD years, mean RP duration
6 ± 3 years) and 35 secondary RP to SSc according to the
ACR/EULAR 2013 criteria (mean age 61 ± 17 SD years, mean
RP duration 11 ± 9 years) (van den Hoogen et al., 2013;
Wigley and Flavahan, 2016).
In patients with secondary RP, SSc duration was determined
by onset of first non-Raynaud symptom clearly attributable to
SSc (LeRoy et al., 1988; LeRoy and Medsger, 2001; Cutolo et al.,
2007b). Furthermore, SSc patients were categorized as having
limited (lcSSc) or diffuse cutaneous SSc (dcSSc) according to
LeRoy criteria, as well as included into the proper pattern of
microangiopathy by nailfold videocapillaroscopy and Cutolo’s
criteria (13 patients showing the “Early,” 13 “Active,” and 9
“Late” pattern of microvascular damage) (LeRoy et al., 1988;
Cutolo et al., 2000, 2004).
Patients with glucose-6-phosphate-dehydrogenase deficiency
or other clinical conditions contraindicating the use of
aminaphtone were excluded from the study.
Further 46 patients with RP (10 primary RP, mean age
56 ± 12 SD years, mean RP duration 8 ± 4 years; 36 secondary
RP to SSc, mean age 63 ± 11 SD years, mean RP duration
12 ± 10 years) were also enrolled as a control group (nailfold
videocapillaroscopy patterns: 14 “Early,” 13 “Active,” and 9 Late”).
Aminaphtone Treatment and
Concomitant Medications
Aminaphtone was administered 75 mg twice daily in addition
to current treatments, as our usual clinical practice in RP
patients, due to its ability to ameliorate the capillary resistance
and permeability and to inhibit erythrocyte aggregation at
microcirculation level (as reported inside technical sheet). The
posology was in agreement with that reported inside the technical
data sheet of the drug.
The exclusion criteria were: treatment with drugs that
could potentially influence peripheral blood perfusion (iloprost,
calcium channel blockers) and presence of recent digital ulcers
requiring bosentan administration.
The inclusion criteria were: patients on stable drug regimen
since at least 2 months prior to study entry, no changes made
during the follow-up, treatment free period of at least 2 months
from prostanoids and endothelin-1 receptor antagonists.
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Concomitant treatments in patients treated with aminaphtone
were: aspirin (average dosage 100 mg/die, used by 34 patients),
proton pump inhibitors (30 patients), antihypertensive drugs
(4 patients), cyclosporine (average dosage 150 mg/die, 6
patients), methotrexate (average dosage 10 mg/die, 4 patients).
Concomitant treatments in control group were: aspirin (average
dosage 100 mg/die, used by 34 patients), proton pump inhibitors
(31 patients), antihypertensive drugs (6 patients), cyclosporine
(average dosage 150 mg/die, 5 patients), methotrexate (average
dosage 10 mg/die, 3 patients).
Evaluation of Skin Blood Perfusion by
Laser Speckle Contrast Analysis (LASCA)
Blood perfusion was measured as perfusion units (PU) in all
patients by LASCA technique (PeriCam PSI, Perimed, Sweden),
as previously reported (Ruaro et al., 2014, 2016; Sulli et al., 2014;
Lambrecht et al., 2016), at the level of dorsal and palmar aspect
of hands and face, at baseline (W0), after one (W1), four (W4),
twelve (W12) and twenty-four (W24) weeks of aminaphtone
treatment, and after one (W25) and five (W29) weeks since
treatment discontinuation. Raynaud’s condition score (RCS) and
both frequency and duration of Raynaud’s attacks were assessed
at the same time (see below). For acclimatization, each patient
stayed inside the building for a minimum of 15 min before
the blood perfusion was examined, at room temperature of
about 23◦C.
After image recording, different regions of interest (ROIs)
were drawn at the fingertip level, periungual areas, dorsum and
palm of hands, tip of noise, and whole face (Sulli et al., 2014;
Ruaro et al., 2016). Blood perfusion was measured inside the ROIs
(see example in Figure 1). The evaluator was blind to both patient
treatment and time of visit. For each anatomic area, the average
BP was calculated by summing the perfusion values of the two
sides, left and right.
All instrumental technical parameters were standardized for
all patients and used at follow-up visits.
Clinical Evaluation of Raynaud’s
Symptoms
The clinical efficacy of aminaphtone on RP symptoms was
evaluated at baseline (W0), after one (W1), four (W4), twelve
(W12) and twenty-four (W24) weeks of treatment, and after one
(W25) and five (W29) weeks since treatment discontinuation.
The Raynaud condition score (RCS) that evaluates the limitation
of daily activity on a scale from 1 to 10 (10 represents the total
inability to do any activity) was used (Pope, 2011; Bose et al.,
2015). Furthermore, the frequency (average number of event
during the day) and duration (in minutes) of Raynaud’s attacks
were also recorded.
Nailfold Videocapillaroscopy (NVC)
All patients were assessed by nailfold videocapillaroscope (NVC),
equipped with a 200× contact lens, connected to image analysis
software (Videocap, DS MediGroup, Milan, Italy). Severity of
microangiopathy was detected according to the proper pattern of
microvascular damage (“Early,” “Active,” or “Late”), as previously
reported (Cutolo et al., 2000, 2004; Sulli et al., 2008).
Statistical Analysis
Statistical analysis was carried out by non-parametric tests. The
Wilcoxon signed-rank test was used to compare paired groups
of variables, and Mann–Whitney U test to compare unpaired
groups of variables. Kruskal–Wallis test was used to compare
continuous variables with nominal variables with more than two
FIGURE 1 | Assessment of blood perfusion. Example of evaluation of blood perfusion by LASCA technique at the level of dorsal (A) and palmar (B) aspect of hands,
respectively, at baseline (W0), after one (W1), four (W4), twelve (W12) and twenty-four (W24) weeks of treatment with aminaphtone in patient F.B. (Blue color = low
blood perfusion, yellow color = intermediate blood perfusion, red color = high blood perfusion (White circles = regions of interest for perfusion measuring at the level
of dorsum, periungual, palm and fingertip areas).
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levels. Friedman test was employed to detect differences across
multiple related comparisons. The p values lower than 0.05 were
considered statistically significant.
RESULTS
Clinical characteristics of enrolled patients are reported
in Table 1.
Despite colder period of the year, progressive statistically
significant increase of blood perfusion was observed from W0
to W12 in all skin areas of RP patients (p < 0.001 for all skin
areas) (see Figure 2 and Table 2A for perfusion values and
statistical significance at single times). From W12 to W24 no
further increase of blood perfusion was observed (Table 2A).
Noteworthy was the fact that all patients on aminaphtone
treatment had an increase of blood perfusion from W0 to W1;
likewise 38/44 patients from W1 to W4, 36/43 from W4 to W12
and 8/43 patients from W12 to W24 had a further increase of
blood perfusion.
A progressive statistically significant decrease of RCS,
frequency of Raynaud’s attacks/day and their duration was also
recorded from W0 to W12 (p < 0.0001 for all) (see Figure 2 and
Table 3A for clinical values and statistical significance at single
times). From W12 to W24 clinical symptoms did not change
significantly (Table 2A).
TABLE 1 | Clinical findings in patients with Raynaud’s phenomenon.
Total RP
patients
Age
(years)
Gender
Female/Male
Weight (kg) PRP RP duration (years) NVC patterns
Early/Active/Late
lcSSc/dcSSc
PRP SRP-SSc
AMI No. of patients 46 40/6 11 35 13/13/9 24/11
mean ± SD 58 ± 11 65.1 ± 5.9 6 ± 3 11 ± 9
CNT No. of patients 46 40/6 10 36 14/13/9 25/11
mean ± SD 60 ± 11 64.8 ± 6.3 7 ± 4 11 ± 10
AMI = aminaphtone treated group; CNT = control untreated group; RP = Raynaud’s phenomenon; PRP = primary Raynaud’s phenomenon; SRP = secondary
Raynaud’s phenomenon; SSc = systemic sclerosis; NVC = nailfold videocapillaroscopy; Early, Active, Late = patterns of microangiopathy; lcSSc = limited cutaneous
SSc; dcSSc = diffuse cutaneous SSc. AMI vs. CNT: p = not significant for all results.
FIGURE 2 | Blood perfusion and clinical trends during aminaphtone treatment. Variation of blood perfusion (BP) in six skin areas from baseline (W0) to twenty-four
(W24) weeks during aminaphtone treatment, and after one (W25) and five (W29) weeks since treatment discontinuation, in all patients with Raynaud’s phenomenon.
Variation of Raynaud Condition Score (RCS), Raynaud’s frequency (number of daily attacks) and duration (minutes) are also reported. Charts report means along with
standard deviation values (PU = perfusion units). See Table 2 for statistical significances.
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The results concerning clinical efficacy were similar in both
primary and secondary RP patients (see Tables 3A,B for further
details), as well as in patients with limited or diffuse skin disease,
and in patients with “Early,” “Active,” or “Late” NVC pattern of
microangiopathy.
Any statistically significant change as in blood perfusion, as
in clinical symptoms (RCS, frequency and duration of Raynaud’s
attacks), was not observed in the control group of RP patients
(either primary or secondary RP) between W0 and W24 (see
Table 2B for perfusion and clinical values).
One and five weeks after treatment discontinuation, a
progressive reduction of skin blood perfusion was recorded
(see Table 2A for statistical details). However, five weeks after
aminaphtone discontinuation blood perfusion values were yet
significantly higher than those at baseline in the majority of skin
areas (Table 2A). Also clinical efficacy was still sustained 5 weeks
after treatment discontinuation (Table 2A).
Serious adverse events were not observed during the study.
Aminaphtone was stopped in two patients due to headache,
which recovered one days after treatment discontinuation.
One patient was lost during follow-up. Blood cell count, liver
aminotransferase, and creatinine values were also routinary
assessed every 3 months and no abnormal variation of these
parameters was observed.
DISCUSSION
This is the first feasibility study that has evaluated the effects of
aminaphtone treatment on both skin blood perfusion and clinical
symptoms in patients affected by either primary or secondary RP.
The study demonstrates that aminaphtone treatment increases
in short-time skin blood perfusion at the level of hands and face,
as well as ameliorates RP clinical symptoms, with a sustained
efficacy until 6 months. The results were similar for both primary
and secondary RP patients. Of interest, any statistically significant
difference was not observed concerning skin blood perfusion and
RP clinical improvement between patients with different pattern
of nailfold microangiopathy (“early,” “active,” or “late”), as well as
between lcSSc and dcSSc patients, supporting the clinical efficacy
of aminaphtone in different subgroups of RP patients (Sulli
et al., 2017). Furthermore, skin blood perfusion increased after
aminaphtone treatment also at the level of face, which usually
shows similar blood perfusion values as in SSc patients as in
healthy subjects (Sulli et al., 2014; Ruaro et al., 2016).
This study demonstrates also a progressive statistically
significant improvement of the RCS, frequency and duration of
RP attacks from baseline to 12 weeks of treatment. Similar results
have been highlighted even by other studies where endothelin
receptor antagonists or phosphodiesterase 5 inhibitors were
administered to patients with secondary RP (Selenko-Gebauer
et al., 2006; García de la Peña-Lefebvre et al., 2008; Roustit et al.,
2013; Kamata and Minota, 2014; Lee et al., 2014).
Raynaud’s phenomenon significantly impacts on quality of life
in all subjects. It provokes the deterioration of patient quality
of life, not only in terms of pain, but also due to the extreme
difficulty in performing normal daily activities. An international
survey involving 443 people with self-reported RP showed that
64% had poor ability to control their attacks and only 16%
believed that one current medication was effective (Hughes
et al., 2015). Treatments were generally considered tolerable but
seldom fully effective, and the results confirmed an unmet need
for new treatments, as the approach to the management of the
disorder was based on published information, expert opinion,
and current practices (Hughes et al., 2015).
Current treatments for RP include calcium channel blockers,
i.v. prostanoids, and topical glyceryl trinitrate (applied locally
to the digits), while key strategic treatment are the increased
use of phosphodiesterase type V inhibitors in severe RP (Kowal-
Bielecka et al., 2017). Other treatments being researched include
botulinum toxin (for severe digital ischemia/ulceration), and
several other drugs including oral prostanoids (Shah et al.,
2013; Fardoun et al., 2016; Motegi et al., 2016; Z˙ebryk and
Puszczewicz, 2016). In view of costs and feasibility, the experts
in EULAR propositions recommended that calcium antagonists
were first-line therapy in the treatment of secondary RP in SSc,
and intravenous prostanoids were recommended when calcium
antagonists had failed. As both types of drugs may induce side
effects of vascular origin, the experts recommend particular
attention if prostanoids are combined with calcium antagonists
(Kowal-Bielecka et al., 2009).
Recently, increased availability and interest in nailfold
capillaroscopy and laser technologies, by assessing morphological
and functional capillary/microcirculatory variations, paves the
way for studies on early intervention and vascular protection in
RP/SSc patients (Cutolo et al., 2010a,b, 2013, 2014; Rosato et al.,
2010; Ruaro et al., 2014).
Our results highlight the effectiveness of aminaphtone in
the treatment of RP. An interesting observation, not reported
among the results of the study, was that some patients with
oedematous/puffy fingers (8 patients complaining of primary
RP, and 6 patients affected by secondary RP to SSc; among
these 5 with the Early and 1 with the Active pattern of
microangiopathy) reported an improvement, until complete
resolution of symptoms, during treatment with aminaphtone.
This was possibly related to the reduction of the oedematous
phase that this molecule has been shown to induce in several
studies (De Anna et al., 1989; Martinez-Zapata et al., 2016).
The mechanism of actions of aminaphtone is unclear.
Recent studies have reported that aminaphtone reduces vessel
permeability and tissue oedema (De Anna et al., 1989; Scorza
FIGURE 3 | Structure formula of aminaphtone (C18-H15-N-O4).
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et al., 2008a,b). Furthermore, results from in vitro studies suggest
that among different mechanisms of action, aminaphtone may
down-regulate the E-selectin (ELAM-1), Vascular Cell Adhesion
Molecule-1 (VCAM-1) and Intra Cellular Adhesion Molecule-
1 (ICAM-1) expression, as well as cytokine/chemokine and
endothelin-1 production on cultured human endothelial cells
(Scorza et al., 2008a,b; Salazar et al., 2016). Of note, endothelin-
1 generates vasoconstriction on microvessels and its serum level
is increased in both patients with primary and secondary RP
(Sulli et al., 2009).
Aminaphtone down-regulates both gene transcription and
protein production of almost all the most important molecules
responsible for the inflammatory state, including IL-6 (Salazar
et al., 2016). It also decreases the levels of TGF-β which can lead
to pulmonary fibrosis by activating the fibroblasts to produce an
excessive deposition of collagen (Salazar et al., 2016).
Probably all these actions of aminaphtone support the
first results of Parisi et al. (2015) who reported the possible
effectiveness of aminaphtone in association with standard
therapy in RP patients, resulting in a synergic effect on
vasospastic phenomena.
As reported inside technical sheet, concerning
pharmacokinetic properties, administered to humans
aminaphtone is partially metabolized to phthiocol and eliminated
through the urine within the 72nd hour. The maximum excretion
level was observed to be 6 h after administration. Concerning
preclinical safety data, the tests of acute toxicity (4 animal species
for doses up to 3 g/kg), subacute toxicity (2 animal species up to
100 mg/kg, for 90 days) and chronic toxicity (50 mg/kg in the dog
for 280 days) showed no symptoms of tissue lesions or changes
in organ functions. Aminaphtone also had no teratogenic or
mutagenic effects. The structure formula of aminaphtone is
reported in Figure 3.
This study has some limitations. It’s not randomized, not
blind, and underpowered to detect small treatment effects.
However, the high statistical significance of the results despite
the small cohort of enrolled patients suggests the possibility to
confirm these results by performing larger randomized clinical
studies. The two patient groups cannot be completely compared:
blood perfusion was assessed only at basal time and after
6 months in the control group, as the decision of including a
control group into this pilot study came later, after enrolment
completion. In order to assess the trend of blood perfusion
during the same months of the year in both patient groups,
a control group of patients who performed the first LASCA
evaluation in the same month of the aminaphtone-treated
group was enrolled. Also the possible effect of aminaphtone
on digital ulcer healing/prevention was not assessed in this
study, as it was not addressed to this endpoint. In both groups,
aminaphtone and control group, only one patient developed
a new digital ulcer; however, patients in the control group
were showing a less aggressive disease at baseline. Despite this,
aminaphtone treatment was found effective in increasing skin BP
and ameliorating RP clinical symptoms, while any modification
of skin BP was not detected in the untreated group of patients.
Another points is the nature of this uncontrolled clinical study
that does not provide the sureness that all patients have taken two
tablets of aminaphtone per day for six months (the treatment cost
is covered by patient in our country): at best of our knowledge,
the patients declared adherence to the treatment, but this may
not be proven and the eventuality might be the cause of a slight
reduction of blood perfusion after week 12 of treatment. Finally,
the seasonal variation of temperature should not have influenced
the results of the study, as all patients were enrolled in November,
and the study carried out during the six colder months of the year.
By considering recent data showing that 5–15% of patients
diagnosed as affected by primary RP may shift to secondary
RP during follow-up, the possible role of aminaphtone in the
prevention of this transition should be longitudinally investigated
(Cutolo et al., 2007a; Ingegnoli et al., 2010; Bernero et al., 2013;
Trombetta et al., 2016; Gualtierotti et al., 2017).
CONCLUSION
Aminaphtone treatment was well tolerated and improved in
short time skin blood perfusion and RP clinical symptoms,
with a sustained efficacy until six months. A randomized, blind,
controlled, clinical trial including a larger number of subjects is
advisable to confirm these early results and to assess the possible
role of aminaphtone also in the treatment/prevention of other
SSc-related clinical manifestations.
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